Sunday , November 24 2024
Home / Mike Norman Economics / Randomized but unblinded experiment on vitamin D as a coronavirus treatment. Let’s talk about what comes next. (Hint: it involves multilevel models.) — Andrew Gelman

Randomized but unblinded experiment on vitamin D as a coronavirus treatment. Let’s talk about what comes next. (Hint: it involves multilevel models.) — Andrew Gelman

Summary:
Of interest statistically.Statistical Modeling, Causal Inference, and Social ScienceRandomized but unblinded experiment on vitamin D as a coronavirus treatment. Let’s talk about what comes next. (Hint: it involves multilevel models.) Andrew Gelman | Professor of Statistics and Political Science and Director of the Applied Statistics Center, Columbia UniversityAnother studyPLOSVitamin D sufficiency, a serum 25-hydroxyvitamin D at least 30 ng/mL reduced risk for adverse clinical outcomes in patients with COVID-19 infection Zhila Maghbooli,Mohammad Ali Sahraian ,Mehdi Ebrahimi,Marzieh Pazoki,Samira Kafan,Hedieh Moradi Tabriz,Azar Hadadi,Mahnaz Montazeri,Mehrad Nasiri,Arash Shirvani,Michael F. Holick

Topics:
Mike Norman considers the following as important:

This could be interesting, too:

Matias Vernengo writes Elon Musk (& Vivek Ramaswamy) on hardship, because he knows so much about it

Lars Pålsson Syll writes Klas Eklunds ‘Vår ekonomi’ — lärobok med stora brister

New Economics Foundation writes We need more than a tax on the super rich to deliver climate and economic justice

Robert Vienneau writes Profits Not Explained By Merit, Increased Risk, Increased Ability To Compete, Etc.


Of interest statistically.

Statistical Modeling, Causal Inference, and Social Science
Randomized but unblinded experiment on vitamin D as a coronavirus treatment. Let’s talk about what comes next. (Hint: it involves multilevel models.)
Andrew Gelman | Professor of Statistics and Political Science and Director of the Applied Statistics Center, Columbia University

Another study

PLOS
Vitamin D sufficiency, a serum 25-hydroxyvitamin D at least 30 ng/mL reduced risk for adverse clinical outcomes in patients with COVID-19 infection
Zhila Maghbooli,Mohammad Ali Sahraian ,Mehdi Ebrahimi,Marzieh Pazoki,Samira Kafan,Hedieh Moradi Tabriz,Azar Hadadi,Mahnaz Montazeri,Mehrad Nasiri,Arash Shirvani,Michael F. Holick

Mike Norman
Mike Norman is an economist and veteran trader whose career has spanned over 30 years on Wall Street. He is a former member and trader on the CME, NYMEX, COMEX and NYFE and he managed money for one of the largest hedge funds and ran a prop trading desk for Credit Suisse.

Leave a Reply

Your email address will not be published. Required fields are marked *